BACKGROUND AND OBJECTIVES:
There is increasing evidence for the key role of osteocytes in the regulation of bone remodeling. One of the main products of these cells, sclerostin, inhibits bone formation and may also stimulate bone resorption. To our knowledge, there are few data in prostate cancer (PC) patients especially in patients with hypogonadism related to androgen deprivation therapy (ADT).
DESIGN, SETTING AND PATIENTS:
Cross-sectional study including 25 patients with PCa treated with androgen deprivation therapy (ADT), 34 patients with untreated PCa, and 22 healthy controls.
• Serum total testosterone (T) and estradiol (E2) were measured by ECLIA. Free testosterone, bioavailable testosterone, free estradiol and bioavailable estradiol were calculated.
• Markers of bone turnover were determined as follows: total osteocalcin (OC), serum carboxyterminal cross-linked telopeptide of type I collagen (CTX) , and tartrate-resistant acid phosphatase 5b (TRAP5b)
• Lumbar spine and femoral bone mineral density (BMD) were measured by dual X-Ray absorptiometry (Hologic QDR 4500). World Health Organization criteria for osteoporosis were used.
• Serum sclerostin was measured using quantitative sandwich enzyme-linked immunosorbent assay (ELISA) developed by Biomedica (Austria).
Intra e inter-assay variability by our laboratory were and 4% and 3%, respectively. Sclerostin measurements are reported throughout in picomoles per liter (pmol/L) and lower limit of detection was <10 pmol/L.
RESULTS:

CONCLUSIONS:
1) Circulating sclerostin levels are significantly increased in patients with prostate cancer and particularly in those with androgen-deprivation therapy.
2) The inverse relationship between sclerostin and testosterone in these patients suggests that androgens are key regulators of bone metabolism in this population.
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